New research indicates administration of the antibiotic azithromycin late in pregnancy may be tied to a lower risk of neurodevelopmental disorders (NDDs) than other antibiotics used for bacterial infections during pregnancy, researchers reported this week in JAMA Network Open.
An estimated 37% of US women are exposed to antibiotics during pregnancy for bacterial infections, including respiratory and sexually transmitted infections, and roughly 3% use azithromycin, which is also used in expectant mothers to help prevent surgical-site infection after cesarean and vaginal delivery. But the effects of azithromycin use on neurodevelopmental outcomes like autism in children remains undetermined, and studies on the topic have reported conflicting findings, according to a team led by researchers with the University of Rhode Island College of Pharmacy.
To evaluate the risk of NDD's in children exposed to azithromycin during pregnancy, the researchers examined data from an administrative health claims database on a cohort of mother-infant pairs who filled at least one antibiotic prescription or were unexposed to antibiotics during pregnancy from January 2012 through December 2023. The primary outcome was the incidence of NDDs, including attention-deficit/hyperactivity disorder, autism spectrum disorder, speech and language disorder (SLD), developmental coordination disorder, and behavioral disorders.
Significantly lower risk than with other antibiotics
Among the 15,527 mother-infant dyads, 742 (4.8%) were exposed to azithromycin and 3,079 (19.8%) to other antibiotics, while 11,706 (75.4%) were not exposed any antibiotics during pregnancy.
After a mean follow-up of five-and-a half years, the researchers found no difference in the risk of any NDDs in children exposed to azithromycin versus other antibiotics during the entire or early pregnancy periods, or compared with those unexposed to antibiotics. But in late pregnancy (from 20 weeks of gestation to delivery), they found a significantly lower risk of composite NDDS (adjusted hazard ratio [AHR], 0.69) and SLD (AHR, 0.59) in azithromycin-exposed children compared with those exposed to other antibiotics.
The study authors caution, however, that azithromycin prescribing during pregnancy "should remain guided by clinical necessity and existing safety recommendations."
"Additional studies using larger and more diverse populations are warranted to confirm these results," they concluded.